Publicacións nas que colabora con María Jesús Lamas Díaz (16)

2021

  1. Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy

    Cancer Chemotherapy and Pharmacology, Vol. 88, Núm. 5, pp. 813-823

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  3. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

    Journal of Chemotherapy, pp. 1-13

  4. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

2019

  1. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment

    Head and Neck, Vol. 41, Núm. 8, pp. 2704-2715

2015

  1. Long Survival and Severe Toxicity under 5-Fluorouracil-Based Therapy in a Patient with Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS

    Mayo Clinic Proceedings, Vol. 90, Núm. 9, pp. 1298-1303

2014

  1. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer

    Human Genetics, Vol. 133, Núm. 5, pp. 525-534

2013

  1. A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12

    BMC Genomics, Vol. 14, Núm. 1

  2. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations

    Carcinogenesis, Vol. 34, Núm. 2, pp. 314-318

  3. Corrigendum

    Carcinogenesis

  4. Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

    Pharmacogenomics Journal, Vol. 13, Núm. 3, pp. 209-217

2012

  1. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens

    Cancer Chemotherapy and Pharmacology, Vol. 69, Núm. 6, pp. 1591-1599

  2. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 1, pp. 138-144

2011

  1. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer

    Pharmacogenomics, Vol. 12, Núm. 3, pp. 433-442

2010

  1. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response

    Pharmacogenomics, Vol. 11, Núm. 6, pp. 747-761